AI in cancer detection and treatment
Roche announced on May 9, 2026, its acquisition of PathAI, an AI-powered digital pathology company, for up to $1.05 billion to enhance AI-driven diagnostics and companion diagnostics for oncology trials. As of May 13, 2026, significant advancements in AI for cancer detection and treatment continue, with Argonne National Laboratory's IDEAL project using AI to screen billions of molecular compounds to accelerate drug discovery, and the development of SPARK, an agentic AI framework for analyzing tumor pathology data. Other innovations include PrecisionView, an AI-powered handheld endomicroscope for real-time diagnostics, and STimage, an AI screening tool that enhances pathology by predicting cancer types and prognosis. The UAE also announced the development of ISM0387, the first fully AI-discovered and developed drug candidate showing promise against solid tumors.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
May 2026 — 8 developments
Scientists have developed SPARK, an agentic AI framework designed to autonomously analyze complex pathology data from tumors.
Scientists have developed SPARK, an agentic AI framework designed to autonomously analyze complex pathology data from tumors. This approach helps researchers uncover hidden biological information within tumors, aiming to accelerate cancer research by providing novel insights.
Argonne National Laboratory is using AI and high-performance computing in its IDEAL project to scree…
Argonne National Laboratory is using AI and high-performance computing in its IDEAL project to screen billions of molecular compounds, aiming to accelerate cancer drug discovery and vaccine development. The project has the potential to reduce development timelines from years to months. Additionally, the TRIALSCOPE framework, developed by Providence and Microsoft, has demonstrated success in replicating outcomes of lung and pancreatic cancer clinical trials.
Providence and Microsoft have partnered to create TRIALSCOPE, an AI-enabled framework designed to simulate clinical trials and more efficiently identify eligible participants.
Providence and Microsoft have partnered to create TRIALSCOPE, an AI-enabled framework designed to simulate clinical trials and more efficiently identify eligible participants. The U.S. Food and Drug Administration (FDA) is also piloting a 'real-time clinical trials' program aimed at improving the efficiency, speed, and quality of decision-making in early-phase trials.
Generative AI models are emerging as powerful tools to understand cancer complexity by integrating i…
Generative AI models are emerging as powerful tools to understand cancer complexity by integrating image, molecular, and clinical data, potentially improving diagnostic accuracy and personalized therapies. Additionally, AI algorithms like TrialGPT are being developed to enhance clinical trial processes by improving patient recruitment and matching, addressing disparities in trial access.
Researchers from Rice University and MD Anderson Cancer Center have developed PrecisionView, an AI-powered handheld endomicroscope for real-time diagnostics at the point of care.
Researchers from Rice University and MD Anderson Cancer Center have developed PrecisionView, an AI-powered handheld endomicroscope for real-time diagnostics at the point of care. Separately, Australian scientists created STimage, an AI screening tool that enhances pathology by predicting cancer types and prognosis using spatial biology analysis, aiming for faster, more accurate diagnoses and improved access to specialist care.
Roche is acquiring PathAI, a company specializing in AI-powered digital pathology, for up to $1.
Roche is acquiring PathAI, a company specializing in AI-powered digital pathology, for up to $1.05 billion. This strategic move aims to enhance Roche's capabilities in AI-driven diagnostics and companion diagnostics for oncology trials, ultimately improving cancer diagnosis and personalized treatment development.
Scientists have developed an AI screening tool called STimage that uses spatial biology analysis to help pathologists detect hidden genetic markers of cancer in tissue samples.
Scientists have developed an AI screening tool called STimage that uses spatial biology analysis to help pathologists detect hidden genetic markers of cancer in tissue samples. The tool has shown accuracy in predicting breast, skin, and kidney cancers, potentially leading to faster diagnoses and personalized treatments.
Researchers at Johns Hopkins Medicine have developed a novel AI tool that analyzes complex biological data to predict patient response to cancer immunotherapy.
Researchers at Johns Hopkins Medicine have developed a novel AI tool that analyzes complex biological data to predict patient response to cancer immunotherapy. The tool aims to personalize treatment by identifying the most effective immunotherapies for individual patients, thereby improving outcomes.
April 2026 — 51 developments
A Mayo Clinic-developed AI model, REDMOD, has demonstrated the ability to detect pancreatic cancer on routine CT scans up to three years before clinical diagnosis.
A Mayo Clinic-developed AI model, REDMOD, has demonstrated the ability to detect pancreatic cancer on routine CT scans up to three years before clinical diagnosis. This advancement is part of broader progress in AI for cancer detection, pathology, and drug development, with AI models also being created to signal cancer presence via molecular sensors.
The UAE has announced the development of ISM0387, the first fully AI-discovered and developed drug c…
The UAE has announced the development of ISM0387, the first fully AI-discovered and developed drug candidate showing promise against solid tumors, including aggressive brain cancers. Researchers have also developed AI-generated molecular sensors capable of detecting cancer in its earliest stages through simple urine tests, offering potential for at-home diagnostics.
LG AI Research and Vanderbilt University Medical Center have developed an agentic AI system designed to streamline the entire cancer treatment workflow to a single day.
LG AI Research and Vanderbilt University Medical Center have developed an agentic AI system designed to streamline the entire cancer treatment workflow to a single day. New research also indicates Hologic's AI-driven breast cancer detection technologies can support radiologists, and an AI framework has been developed to predict PIK3CA mutations in breast cancer, potentially improving personalized treatment decisions.
The Hong Kong University of Science and Technology (HKUST) has developed PRET, a new AI pathology an…
The Hong Kong University of Science and Technology (HKUST) has developed PRET, a new AI pathology analysis system that accurately identifies multiple cancer types with minimal samples and without additional training. PRET demonstrated superior performance over existing methods in 20 out of 23 international benchmark datasets, achieving an Area Under the Curve (AUC) exceeding 97% in 15 tasks. Additionally, an AI-designed TNIK inhibitor has entered human testing, and Paradigm Health has launched an AI-powered platform to accelerate clinical trials.
Johns Hopkins Medicine's Cancer AI Alliance (CAIA) is advancing AI-driven diagnosis and treatment fo…
Johns Hopkins Medicine's Cancer AI Alliance (CAIA) is advancing AI-driven diagnosis and treatment for brain cancer, while a new study shows large language models can generate more comprehensive cancer pathology report summaries. Evaxion's AI-Immunology platform has also shown high precision in identifying targets for personalized cancer vaccines, with new data from a Phase 2 trial.
An AI system named 'MedScan AI' has achieved 95% accuracy in early cancer detection with a false pos…
An AI system named 'MedScan AI' has achieved 95% accuracy in early cancer detection with a false positive rate below 3%, and is being integrated into over 1,000 healthcare facilities worldwide. Researchers have also developed an AI model that designs peptides for molecular sensors capable of detecting cancer-linked proteases in urine tests for early detection.
The AACR Annual Meeting 2026 will feature AI in cancer research, with a Plenary Session on April 19, 2026.
The AACR Annual Meeting 2026 will feature AI in cancer research, with a Plenary Session on April 19, 2026. Generative AI has achieved diagnostic accuracy rates of 95%-98% for lung cancer, and AI in breast cancer screening has shown a 10.4% increase in detection, reducing notification times from 14 to 3 days. Additionally, generative AI for cancer diagnosis was among breakthrough projects awarded €118 million by the European Innovation Council on April 5, 2026.
OpenAI has launched GPT-Rosalind to accelerate drug discovery by helping researchers extract insights from data.
OpenAI has launched GPT-Rosalind to accelerate drug discovery by helping researchers extract insights from data. A new AI-powered method, PhenMap, has been developed to predict patient response to bowel cancer treatment, potentially sparing thousands from ineffective therapies.
AI is accelerating drug discovery with tools like OpenAI's GPT-Rosalind and AWS's Amazon Bio Discove…
AI is accelerating drug discovery with tools like OpenAI's GPT-Rosalind and AWS's Amazon Bio Discovery, while the DELFI blood test shows promise for early detection of liver and lung cancers. New AI frameworks like ClAIrVue are improving medical imaging analysis, and AI-designed small molecules are advancing into clinical trials.
2026 is anticipated to be a pivotal year for AI in clinical trials, moving from exploration to execu…
2026 is anticipated to be a pivotal year for AI in clinical trials, moving from exploration to execution, with AI expected to reshape trial design through simulation and the use of richer data. AI systems are also showing promise in identifying individuals at higher risk of melanoma by analyzing routine health data, paving the way for more targeted screening. Major pharmaceutical companies are transitioning to AI platforms for drug R&D, with generative AI producing small-molecule candidates advancing into human testing.
The FDA has approved Paige Prostate, the first AI-based pathology product for detecting cancer in prostate biopsies, significantly improving accuracy.
The FDA has approved Paige Prostate, the first AI-based pathology product for detecting cancer in prostate biopsies, significantly improving accuracy. A new AI tool, MangroveGS, can predict cancer spread with approximately 80% accuracy by analyzing gene patterns.
Ryght AI has launched the world's first free AI-powered clinical trial site search engine.
Ryght AI has launched the world's first free AI-powered clinical trial site search engine. This tool aims to accelerate cancer drug discovery, potentially reducing the process from a decade to months or years and saving billions of dollars.
Evaxion A/S announced new phase 2 data for its personalized cancer vaccine EVX-01, with its AI-Immunology™ platform achieving an 86% success rate in identifying vaccine targets.
Evaxion A/S announced new phase 2 data for its personalized cancer vaccine EVX-01, with its AI-Immunology™ platform achieving an 86% success rate in identifying vaccine targets. Novartis CEO Vas Narasimhan joined the board of AI company Anthropic, and AbbVie is leveraging generative AI for drug discovery and clinical trial optimization.
ViewsML's AI platform offers biomarker insights from pathology slides without staining, saving time and cost.
ViewsML's AI platform offers biomarker insights from pathology slides without staining, saving time and cost. Additionally, advanced AI models in a Swedish study accurately identified individuals with up to a 33% chance of developing melanoma within five years, paving the way for targeted screening.
Lantern Pharma has launched withZeta.
Lantern Pharma has launched withZeta.ai, an AI co-scientist for rare cancer drug discovery, and Amazon has introduced a system to generate and virtually test thousands of drug molecules. An AI-designed TNIK inhibitor has also shown safety and pharmacodynamic signals in a human trial, accelerating clinical translation.
The National Comprehensive Cancer Network (NCCN) has updated its 2026 guidelines to incorporate AI-based risk assessment for breast cancer using mammogram data.
The National Comprehensive Cancer Network (NCCN) has updated its 2026 guidelines to incorporate AI-based risk assessment for breast cancer using mammogram data. The Clairity Breast AI model is the first FDA-approved tool for predicting 5-year breast cancer risk from mammography.
OpenAI has introduced GPT-Rosalind, an AI model designed to accelerate drug discovery and scientific research by analyzing large datasets.
OpenAI has introduced GPT-Rosalind, an AI model designed to accelerate drug discovery and scientific research by analyzing large datasets. Bristol-Myers Squibb is collaborating with AI startups to optimize clinical trial design and protocol authoring. Additionally, FDA-authorized software is now assisting pathologists in identifying potential cancer in prostate biopsy images.
Waiv has achieved dual CE marking under IVDR for its AI precision tests for breast and colorectal cancer, enabling clinical deployment across EU member states.
Waiv has achieved dual CE marking under IVDR for its AI precision tests for breast and colorectal cancer, enabling clinical deployment across EU member states. These tests aim to improve patient outcomes through AI-driven prognostic risk profiling and MSI screening.
The FDA has released 10 guiding principles for AI in drug development, stressing the need for traceable and explainable logic.
The FDA has released 10 guiding principles for AI in drug development, stressing the need for traceable and explainable logic. MIT and Microsoft researchers are developing AI-designed molecular sensors for early cancer detection, potentially enabling simple urine tests. Weill Cornell Medicine is also training researchers in AI fluency for oncology, emphasizing ethical use.
Lunit and Evaxion are presenting new AI research in oncology, including AI-driven biomarkers and tumor microenvironment analysis, at the AACR Annual Meeting.
Lunit and Evaxion are presenting new AI research in oncology, including AI-driven biomarkers and tumor microenvironment analysis, at the AACR Annual Meeting. AI is also being used to design molecular sensors for early cancer detection and to predict patient response to specific cancer treatments, aiming to personalize therapies and improve outcomes.
Researchers have developed a new AI tool called SIDISH that identifies specific cell groups within tumors driving aggressive cancers, offering a more targeted therapy approach.
Researchers have developed a new AI tool called SIDISH that identifies specific cell groups within tumors driving aggressive cancers, offering a more targeted therapy approach. Amazon Web Services launched 'Amazon Bio Discovery,' an AI-powered platform to accelerate drug discovery. Additionally, an AI tool can now estimate biological age from chest X-rays, and another AI tool is being developed to predict patient response to bowel cancer treatment.
AI systems are now detecting tumors 40% earlier than human radiologists, and pathology AI has achieved 94% diagnostic accuracy, according to AI Magicx.
AI systems are now detecting tumors 40% earlier than human radiologists, and pathology AI has achieved 94% diagnostic accuracy, according to AI Magicx. Insilico Medicine has nominated ISM6200, an AI-designed drug candidate, for the treatment of ovarian cancer and cortisol disorders. Tempus AI has introduced an automated clinical update service for its AI-enabled clinician portal to keep cancer therapy recommendations current.
A study published in April 2026 demonstrated that AI models can identify high-risk melanoma patients, potentially leading to more efficient screening.
A study published in April 2026 demonstrated that AI models can identify high-risk melanoma patients, potentially leading to more efficient screening. Google's AI model has proposed and validated a new drug combination for cancer treatment, and Amazon launched 'Amazon Bio Discovery' to accelerate early-stage drug discovery. Separately, a study found AI-driven chatbots provide problematic medical advice about 50% of the time.
Lantern Pharma has launched 'withZeta.
Lantern Pharma has launched 'withZeta.ai,' described as the world's first multi-agentic AI co-scientist for rare cancer drug discovery. The company is offering subscriptions for this AI platform, with debut events scheduled at Nasdaq MarketSite and AACR 2026.
A study published on April 12, 2026, found that open-source AI models can generate more comprehensiv…
A study published on April 12, 2026, found that open-source AI models can generate more comprehensive summaries of cancer pathology reports than physicians, excelling at capturing critical molecular and genetic findings. Separately, an AI tool is under development to predict bowel cancer patient response to NHS drugs, and South Korea has seen a surge in AI-based medical device approvals, including one that generates medical reports. Additionally, an AI-based liquid biopsy shows promise for detecting brain cancer with about 75% accuracy.
Emerging AI agents can autonomously optimize drug design and development, proposing therapeutic strategies and handling complex, multi-step problems in oncology.
Emerging AI agents can autonomously optimize drug design and development, proposing therapeutic strategies and handling complex, multi-step problems in oncology. Additionally, a new AI-powered chemistry technique called "Chemputation" automates molecule creation for new medications, significantly speeding up drug discovery. Pfizer is also partnering with AI startups to discover new chemical structures for antibody-drug conjugates, aiming to enhance precision in developing advanced cancer treatments.
Daiichi Sankyo is collaborating with Imagene AI to enhance biomarker discovery and predict treatment responses using multimodal AI.
Daiichi Sankyo is collaborating with Imagene AI to enhance biomarker discovery and predict treatment responses using multimodal AI. Nexomic has launched AI-driven precision oncology solutions for patient stratification and therapy selection. Additionally, SeleneX, a new clinical AI platform, has been introduced to detect ovarian cancer earlier and personalize treatment pathways.
Gilead Sciences and Tempus AI have expanded their collaboration to deploy AI and real-world data acr…
Gilead Sciences and Tempus AI have expanded their collaboration to deploy AI and real-world data across Gilead's oncology pipeline, aiming to accelerate the development of novel cancer therapies.
The FDA has approved an AI-powered device that analyzes genetic material in blood samples for early cancer detection.
The FDA has approved an AI-powered device that analyzes genetic material in blood samples for early cancer detection. This approval represents a significant advancement in the application of AI for diagnosing and treating cancer.
Insilico Medicine has nominated ISM6200, a preclinical drug candidate for ovarian cancer and cortisol disorders developed using generative AI.
Insilico Medicine has nominated ISM6200, a preclinical drug candidate for ovarian cancer and cortisol disorders developed using generative AI. Lantern Pharma is showcasing its withZeta.ai platform for rare cancer drug discovery. Additionally, AI tools are showing promise in increasing breast cancer detection rates by over 10% and predicting cancer spread with approximately 80% accuracy.
Ataraxis AI has launched Ataraxis Breast NEO, a new AI test that predicts response to neoadjuvant therapy in early-stage breast cancer patients.
Ataraxis AI has launched Ataraxis Breast NEO, a new AI test that predicts response to neoadjuvant therapy in early-stage breast cancer patients. Separately, a UK study found that AI software 'Mia' can increase breast cancer detection rates by over 10% and reduce healthcare professional workload. PathAI and MedStar Health have also partnered to implement AI-driven digital pathology platforms.
Insilico Medicine has nominated ISM6200, a preclinical candidate targeting NR3C1 for ovarian cancer and other disorders, marking their 29th nomination.
Insilico Medicine has nominated ISM6200, a preclinical candidate targeting NR3C1 for ovarian cancer and other disorders, marking their 29th nomination. Caris Life Sciences launched an AI-driven tool to identify which non-small cell lung cancer patients benefit from chemotherapy. Additionally, a new AI tool shows promise in predicting recurrence for Barrett's esophagus patients.
Beijing has launched a policy initiative to become a global hub for biomedical innovation, focusing on AI-driven drug discovery and surgical robots.
Beijing has launched a policy initiative to become a global hub for biomedical innovation, focusing on AI-driven drug discovery and surgical robots. New research indicates AI can detect cancer early through gut bacteria analysis and voice pattern changes.
Insilico Medicine has leveraged generative AI to design a dual-action cancer drug candidate targetin…
Insilico Medicine has leveraged generative AI to design a dual-action cancer drug candidate targeting PKMYT1, capable of both eliminating the target protein and inhibiting its activity. Fortrea has launched Fortrea Intelligent Technology™ (FIT), an AI-enhanced suite of solutions designed to automate clinical trial workflows and improve oversight. Researchers at the University of Geneva have developed a new AI tool, MangroveGS, capable of predicting cancer spread with approximately 80% accuracy across multiple cancer types.
Researchers are highlighting the phenomenon of AI "mirages" where models may fabricate findings in medical images, underscoring the need for rigorous evaluation frameworks.
Researchers are highlighting the phenomenon of AI "mirages" where models may fabricate findings in medical images, underscoring the need for rigorous evaluation frameworks. PathAI and MedStar Health are partnering to deploy an AI digital pathology platform to enhance diagnostic confidence and speed.
AI is being explored for detecting laryngeal cancer through voice analysis and for identifying liver and lung cancers via new blood tests.
AI is being explored for detecting laryngeal cancer through voice analysis and for identifying liver and lung cancers via new blood tests. Generative AI and LLMs are also showing potential in precision oncology by aiding oncologists in interpreting genomic data and finding suitable clinical trials.
A dual-perspective AI model has achieved over 96% accuracy in early lung cancer diagnosis by analyzing CT scans from multiple viewpoints.
A dual-perspective AI model has achieved over 96% accuracy in early lung cancer diagnosis by analyzing CT scans from multiple viewpoints. Huawei has developed a pathology AI model that is in clinical use for high-accuracy cancer diagnosis across various types. Furthermore, AI-driven development has facilitated an FDA submission for neladalkib, an ALK-positive non-small cell lung cancer treatment.
Insilico Medicine has utilized generative AI to design a dual-action cancer drug candidate targeting PKMYT1, a protein implicated in tumor growth.
Insilico Medicine has utilized generative AI to design a dual-action cancer drug candidate targeting PKMYT1, a protein implicated in tumor growth. Eli Lilly has entered into a significant collaboration with Insilico Medicine for AI-driven drug discovery, and Roche has expanded its AI capabilities with Nvidia to accelerate therapeutic and diagnostic development.
The global market for AI in clinical trials is projected to reach $6.
The global market for AI in clinical trials is projected to reach $6.5 billion by 2030, with AI reshaping trials by improving safety monitoring and potentially shrinking sizes. A Chinese AI model, Panda, has shown 99.9% specificity and 92.9% sensitivity in detecting pancreatic cancer from CT scans, identifying early-stage cancers missed by doctors. Additionally, an AI tool named Mia successfully detected breast cancer earlier than human radiologists in a UK study.
Medmain Inc.
Medmain Inc. has unveiled a new AI model for automatically detecting Ki-67-positive cells and calculating their labeling index in pathology slides, published on April 5, 2026. Experts predict AI will become foundational in clinical trials, potentially increasing enrollment by 10% to 20% and accelerating completion. Insilico Medicine announced promising preclinical results for its AI-designed CDK12/13 inhibitors targeting resistant cancers.
An AI model can now analyze breast cancer pathology images to identify patients who can safely avoid chemotherapy, potentially sparing thousands from harsh side effects.
An AI model can now analyze breast cancer pathology images to identify patients who can safely avoid chemotherapy, potentially sparing thousands from harsh side effects. Concurrently, there is a growing emphasis on developing robust data infrastructure to enable AI to unlock the complexities of cancer research.
AI systems are now functioning as 'co-scientists' in cancer research, generating drug candidates and guiding experimental design, with ChatGPT challenged to create cancer drugs.
AI systems are now functioning as 'co-scientists' in cancer research, generating drug candidates and guiding experimental design, with ChatGPT challenged to create cancer drugs. The European Innovation Council is funding generative AI projects for cancer diagnosis and treatment, while a new machine-learning model predicts molecular influence on gene expression for drug candidates targeting specific diseases.
The AI tool Mia has demonstrated a 10.
The AI tool Mia has demonstrated a 10.4% increase in breast cancer detection rates and significantly reduced notification times for affected women. Insilico Medicine is showcasing four oncology programs discovered using its generative AI platform at AACR 2026, building on its partnership with Eli Lilly. Challenges in AI adoption for clinical trials persist, with a focus on building trust and maintaining human oversight.
Eli Lilly has committed $2.
Eli Lilly has committed $2.75 billion to Insilico Medicine for AI-discovered drug candidates, signaling strong industry confidence in AI's role in accelerating pharmaceutical R&D. Harvard Medical School scientists have developed a new AI tool, CHIEF, capable of diagnosing cancer, predicting molecular profiles, and forecasting patient survival across multiple cancer types with high accuracy.
Clinical AI has launched MAIA™ Prescreening on Google Cloud Marketplace, an AI-driven patient screen…
Clinical AI has launched MAIA™ Prescreening on Google Cloud Marketplace, an AI-driven patient screening solution designed to expand patient access and accelerate clinical trial timelines. Technology Networks discusses how AI can be used to create synthetic control arms in clinical trials, simulating patient trajectories and predicting outcomes in silico, which could improve trial efficiency and success rates.
Lunit and CellCarta are partnering to accelerate AI-enabled digital pathology workflows for translational research, clinical trials, and companion diagnostic programs.
Lunit and CellCarta are partnering to accelerate AI-enabled digital pathology workflows for translational research, clinical trials, and companion diagnostic programs. Additionally, an AI-powered stroke clinical decision support system has demonstrated improved patient outcomes in a study.
A study at Mass General Brigham Health System found that an AI-assisted patient screening tool significantly reduced the time to determine clinical trial eligibility and enrollment.
A study at Mass General Brigham Health System found that an AI-assisted patient screening tool significantly reduced the time to determine clinical trial eligibility and enrollment. This highlights AI's growing role in clinical trials for improving efficiency in patient recruitment and screening.
A machine learning model is now being used to predict liver cancer risk, outperforming existing tools with routine clinical data.
A machine learning model is now being used to predict liver cancer risk, outperforming existing tools with routine clinical data. Additionally, AI is revolutionizing melanoma detection and treatment through rapid image analysis and personalized approaches, though concerns about biases for darker skin tones are being addressed.
OneMedNet Corporation has formed a strategic collaboration with Onco-Innovations and Inka Health to accelerate oncology drug development using real-world data and AI.
OneMedNet Corporation has formed a strategic collaboration with Onco-Innovations and Inka Health to accelerate oncology drug development using real-world data and AI. Insilico Medicine announced that four of its abstracts, showcasing generative AI-discovered cancer inhibitors, were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Scientists at the UVA School of Medicine have developed a suite of AI tools, including YuelDesign, Y…
Scientists at the UVA School of Medicine have developed a suite of AI tools, including YuelDesign, YuelPocket, and YuelBond, to accelerate drug discovery by designing molecules tailored to protein targets. Additionally, the European Innovation Council is providing funding to projects that utilize generative AI for medical diagnosis and cancer treatment, aiming to accelerate innovation in these critical healthcare areas.
Insilico Medicine is advancing generative AI in drug discovery, showcasing a new therapy candidate f…
Insilico Medicine is advancing generative AI in drug discovery, showcasing a new therapy candidate for HR+/HER2- breast cancer and an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. These advancements are part of their strategy to accelerate drug development.
March 2026 — 41 developments
Eli Lilly has entered a potential $2.
Eli Lilly has entered a potential $2.75 billion partnership with Insilico Medicine for AI-designed preclinical drugs, and the FDA has approved Paige Prostate, the first AI-based pathology product for clinical use. OpenProtein.AI is also expanding its collaboration with Boehringer Ingelheim for AI-driven antibody discovery.
The Drug Design for Global Health (dd4gh) platform has been launched to accelerate drug discovery fo…
The Drug Design for Global Health (dd4gh) platform has been launched to accelerate drug discovery for diseases like malaria, and the Ataraxis Breast CTX AI test predicts individualized chemotherapy benefits for breast cancer patients. Additionally, the European COMPASS project is using AI to develop predictive models for early detection and personalized treatment of cardiotoxicity in cancer patients.
A new AI system creates 3D digital maps of cells for faster, more accurate cancer detection, achieving near-perfect accuracy.
A new AI system creates 3D digital maps of cells for faster, more accurate cancer detection, achieving near-perfect accuracy. Additionally, Bristol Myers Squibb has partnered with Faro to implement AI-powered workflows for improving clinical trial protocols, covering design, drafting, validation, and optimization. An AI-based radiology information system has also been launched in Kazakhstan's Kyzylorda region, capable of detecting tumors as small as 1 millimeter.
Lunit and CellCarta have partnered to accelerate AI-enabled digital pathology for companion diagnost…
Lunit and CellCarta have partnered to accelerate AI-enabled digital pathology for companion diagnostic programs, combining Lunit's AI algorithms with CellCarta's CDx development capabilities. Discovery Life Sciences and Mindpeak have also partnered to advance AI-powered digital pathology for biomarker analysis in global clinical trials. Additionally, an AI model named PRE-Screen-HCC has been developed to predict liver cancer risk with nearly 80% accuracy.
Novo Nordisk reports that AI agents are accelerating both the initiation and completion of their clinical trials, potentially shortening timelines by weeks or months.
Novo Nordisk reports that AI agents are accelerating both the initiation and completion of their clinical trials, potentially shortening timelines by weeks or months.
SEQSTER PDM, Inc.
SEQSTER PDM, Inc. released "1-Click Eligibility," an AI solution to rapidly identify clinical trial participants, accelerating drug development timelines. Spotlight Pathology received £1.4 million in seed funding for its AI software that analyzes digital pathology images for early blood cancer identification. Scientists at the University of Utah created an AI-powered "lab-on-a-chip" device to predict cancer cell sensitivity to targeted therapies for pediatric leukemia.
New AI-based liquid biopsies are showing promise for detecting brain, liver, and lung cancers in early stages by analyzing DNA and immune system signals.
New AI-based liquid biopsies are showing promise for detecting brain, liver, and lung cancers in early stages by analyzing DNA and immune system signals. The generative AI in clinical trials market is projected to reach nearly USD 2 trillion by 2035, driven by the demand for accelerated drug development. Servier has partnered with Insilico Medicine in an $888 million deal to discover and develop oncology therapies using AI.
Google AI's Cell2Sentence-Scale model has proposed and validated a new cancer drug combination, whil…
Google AI's Cell2Sentence-Scale model has proposed and validated a new cancer drug combination, while Purple Biotech is using generative AI to design novel tri-specific antibodies for oncology. Hoth Therapeutics has also launched its AI platform, OpenClaw, to accelerate drug discovery.
Researchers at the University of Chicago have developed a new AI-powered system to assist pathologis…
Researchers at the University of Chicago have developed a new AI-powered system to assist pathologists in diagnosing rare thymic epithelial tumors, potentially improving treatment decisions. Pictor Labs has also launched an on-premises AI virtual staining system, allowing pathology labs to generate digital stains locally.
BostonGene showcased its AI-driven disease modeling platform at JSMO 2026 to accelerate drug development and precision oncology.
BostonGene showcased its AI-driven disease modeling platform at JSMO 2026 to accelerate drug development and precision oncology. myTomorrows and Clínica Universidad de Navarra partnered to enhance AI-powered clinical trial infrastructure in Spain, aiming to improve patient access to treatments. Tempus and Daiichi Sankyo are collaborating to develop AI models specifically for antibody-drug conjugate (ADC) development.
SCL Science is developing cancer vaccines using its AI platform, DeepNeo, with plans to submit an Investigational New Drug (IND) application by 2027.
SCL Science is developing cancer vaccines using its AI platform, DeepNeo, with plans to submit an Investigational New Drug (IND) application by 2027. The AI in Pathology market is projected to reach approximately $1.39 billion by 2025, and the AI in Clinical Trials market is expected to grow at a CAGR of 22.6%.
New AI tools are enhancing cancer diagnosis and treatment by improving mammography accuracy and reducing radiologist workload.
New AI tools are enhancing cancer diagnosis and treatment by improving mammography accuracy and reducing radiologist workload. AI models can now predict cancer metastasis with approximately 80% accuracy and assess immunotherapy response in metastatic breast cancer, potentially guiding treatment decisions.
Purple Biotech is collaborating with Converge Bio to use generative AI for designing and optimizing …
Purple Biotech is collaborating with Converge Bio to use generative AI for designing and optimizing novel tri-specific antibodies, aiming to significantly reduce discovery timelines. RyboDyn has secured seed funding to advance its AI-powered sequencing and discovery platform for identifying new cancer targets, while Tempus AI is partnering with Daiichi Sankyo to leverage AI for clinical development.
Discovery Life Sciences and MindPeak are partnering to integrate AI precision into cancer biomarker …
Discovery Life Sciences and MindPeak are partnering to integrate AI precision into cancer biomarker testing for global clinical trials, aiming to optimize patient selection and enhance diagnostic workflows. AI models are projected to increase trial enrollment by 10% to 20% by eliminating assessment biases and accelerating drug development through agentic AI.
Lantern Pharma is using AI and big data to reduce cancer drug development time by up to 80%, while R…
Lantern Pharma is using AI and big data to reduce cancer drug development time by up to 80%, while Roche has launched a large-scale 'AI factory' with thousands of NVIDIA GPUs to accelerate drug and diagnostic development. New AI-generated sensor systems are being developed to detect cancer early by identifying cancer-linked enzymes, potentially enabling at-home tests, and AI-powered blood tests are emerging for early detection by analyzing DNA fragments and immune system signals.
PharmaMar and Globant have launched a multi-agent AI framework to accelerate oncology research and d…
PharmaMar and Globant have launched a multi-agent AI framework to accelerate oncology research and drug development, reportedly achieving over 90% accuracy and reducing insight time by up to 15-fold. Researchers at Michigan State University have developed a gene-focused machine learning approach that predicts chemical influences on gene expression, leading to the identification of promising therapeutics for aggressive liver cancer and a chronic lung disease.
A new AI system has been developed to reduce the workload of pathologists in cancer diagnosis while maintaining high accuracy.
A new AI system has been developed to reduce the workload of pathologists in cancer diagnosis while maintaining high accuracy. Additionally, a machine learning system is accelerating drug discovery by accurately predicting chemical reaction outcomes, and the MAGIC AI system is being used for early cancer detection by analyzing micronuclei for chromosomal defects.
Recursion Pharmaceuticals utilized its AI platform to advance a cancer drug candidate into clinical testing in 18 months, significantly shortening the typical 42-month timeline.
Recursion Pharmaceuticals utilized its AI platform to advance a cancer drug candidate into clinical testing in 18 months, significantly shortening the typical 42-month timeline. Tools like DeepMind's AlphaFold are also aiding in the search for viable compounds. This acceleration is crucial for faster delivery of new cancer treatments to patients.
Servier is forming strategic partnerships with companies like Insilico Medicine and Iktos to accelerate therapeutic innovation and identify new oncology drug candidates using AI.
Servier is forming strategic partnerships with companies like Insilico Medicine and Iktos to accelerate therapeutic innovation and identify new oncology drug candidates using AI. A review also highlights how AI is optimizing drug delivery and pharmacokinetic modeling in polymer-based cancer therapies, enabling precise drug release and individualized treatment.
A review in the Journal of Hematology & Oncology explores how generative AI can assist oncologists i…
A review in the Journal of Hematology & Oncology explores how generative AI can assist oncologists in precision oncology by interpreting genomic mutations and identifying suitable clinical trials. The review highlights AI models' strong performance in clinical trial matching, with one model, TrialGPT, achieving 87.3% agreement with expert assessments.
A Google AI system has demonstrated superior performance in detecting breast cancer compared to huma…
A Google AI system has demonstrated superior performance in detecting breast cancer compared to human radiologists in an NHS study, identifying more invasive cancers and 25% of interval cancers. Separately, a new AI system called MAGIC can automatically identify cells with early signs of chromosomal abnormalities linked to cancer development, speeding up research. Additionally, a medically trained AI system achieved 96% accuracy in identifying eligible patients for a rare disease clinical trial by analyzing EHR data.
Scientists have developed an AI system, MangroveGS, that analyzes gene-expression signatures to pred…
Scientists have developed an AI system, MangroveGS, that analyzes gene-expression signatures to predict tumor spread with nearly 80% accuracy in colon cancer, and this system also identified gene signatures that predict metastatic potential in other cancers. Separately, agentic AI tools are being utilized to autonomously accelerate drug development processes, from candidate design to reducing clinical trial bottlenecks, aiming to improve research accuracy and reduce failure rates.
A new AI imaging biomarker, the Quantitative Vessel Tortuosity (QVT™) score, can predict patient outcomes and detect early signs of treatment response in non-small cell lung cancer.
A new AI imaging biomarker, the Quantitative Vessel Tortuosity (QVT™) score, can predict patient outcomes and detect early signs of treatment response in non-small cell lung cancer. Additionally, Medidata has unveiled a suite of AI-based virtual companions designed to accelerate drug development and improve patient care in the life sciences industry.
New research indicates that AI in breast cancer screening can detect more invasive cancers and overa…
New research indicates that AI in breast cancer screening can detect more invasive cancers and overall cases, with fewer false positives and recalls compared to human readers, and reduced scan reading time. Additionally, a new AI-based technology called DocTr has demonstrated superior performance in matching doctors and clinical trial sites to studies.
A UK study published in Nature Cancer found that AI can increase breast cancer detection by 10.
A UK study published in Nature Cancer found that AI can increase breast cancer detection by 10.4% and potentially reduce healthcare worker workload by over 30%, with notification times reduced from 14 days to 3 days. Google's AI system also demonstrated improved breast cancer detection accuracy and reduced radiologist workload in UK trials. These advancements aim to assist radiologists in earlier and more accurate cancer detection.
A study presented at the European Congress of Radiology indicates that AI assessment of screening ma…
A study presented at the European Congress of Radiology indicates that AI assessment of screening mammograms can predict the likelihood of breast cancer detection in subsequent screenings. Separately, artificial intelligence is being used to unravel complex cancer mechanisms, leading to new targeted therapies and personalized treatment plans by analyzing vast amounts of cancer data to uncover hidden patterns.
PathAI has received U.
PathAI has received U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI tool designed to analyze skin lesions. Additionally, Medidata is deploying its AI Study Build technology to accelerate oncology clinical trials for The Menarini Group, aiming to reduce trial startup times.
Scientists have developed an AI system called MangroveGS that analyzes gene-expression signatures to predict tumor metastasis with nearly 80% accuracy in colon cancer.
Scientists have developed an AI system called MangroveGS that analyzes gene-expression signatures to predict tumor metastasis with nearly 80% accuracy in colon cancer. Separately, an AI-powered "electronic nose" developed at Linköping University can detect early signs of ovarian cancer in blood samples with 97% accuracy by analyzing volatile substances. USC researchers also created an AI algorithm that automates the detection of rare cancer cells in blood samples in approximately 10 minutes.
Xlue Inc., a startup from Carnegie Mellon University, is using artificial intelligence to identify p…
Xlue Inc., a startup from Carnegie Mellon University, is using artificial intelligence to identify patients at high risk for lung, liver, and pancreatic cancers. Their AI tool, CATCH-FM, is trained on millions of patient medical records to detect early signals of cancer development. The predictive technology aims to allow doctors to recommend earlier screenings, improving the chances of successful treatment, and has shown a 50% accuracy rate for predicting cancer in patients with no prior history.
Northeastern University has developed an AI tool that can diagnose acute myeloid leukemia (AML) and …
Northeastern University has developed an AI tool that can diagnose acute myeloid leukemia (AML) and suggest treatments in as little as one night, potentially cutting down diagnosis-to-treatment time from weeks to a single day. Stanford Medicine has also created Nuclei.io, an AI-based tool designed to increase pathologists' speed, collaboration, and diagnostic accuracy. Additionally, Indian medtech firms are advancing AI diagnostic tools for conditions like brain damage, tuberculosis, and early breast cancer detection.
Indian medtech firms are developing AI diagnostic tools for conditions like brain damage, tuberculosis, and early breast cancer detection.
Indian medtech firms are developing AI diagnostic tools for conditions like brain damage, tuberculosis, and early breast cancer detection. Additionally, an AI-driven system from Cleveland Clinic and Dyania Health has demonstrated a 96.2% accuracy in identifying patients for rare disease clinical trials, significantly improving diversity in participant recruitment.
Researchers at the Arc Institute have developed Evo 2, a biological foundation model trained on 9 tr…
Researchers at the Arc Institute have developed Evo 2, a biological foundation model trained on 9 trillion DNA base pairs, capable of decoding DNA rules and generating new functional sequences. This AI model accurately predicts the effects of complex mutations and shows promise in analyzing cancer-related genes such as BRCA1. The development opens possibilities for programmable biology and enhanced cancer research.
Researchers at MIT and Microsoft have developed an AI model to design molecular sensors for early cancer detection, potentially usable in a urine test.
Researchers at MIT and Microsoft have developed an AI model to design molecular sensors for early cancer detection, potentially usable in a urine test. New research from the University of Warwick warns that many AI pathology tools may rely on 'shortcut learning' rather than genuine biological understanding, raising concerns about reliability. Additionally, a Northeastern University AI tool can analyze patient samples to map genetic mutations and suggest treatments for acute myeloid leukemia (AML) in as little as one night.
Researchers in Taiwan have developed PanMETAI, an AI-powered platform that detects early-stage pancr…
Researchers in Taiwan have developed PanMETAI, an AI-powered platform that detects early-stage pancreatic cancer with up to 94% accuracy using metabolic fingerprints from blood samples. Published in Nature Communications, the tool combines AI with NMR metabolomics to identify subtle metabolic shifts indicative of the disease. This non-invasive method aims to improve the notoriously low survival rate of pancreatic cancer through earlier diagnosis and treatment.
Russian researchers have developed a neural network capable of detecting early-stage breast cancer from CT scans in minutes.
Russian researchers have developed a neural network capable of detecting early-stage breast cancer from CT scans in minutes. The AI system, created by St. Petersburg Electrotechnical University and the Almazov National Medical Research Center, highlights potential cancer signs for physician review and developers claim it reduces clinical error probability by approximately 20%.
A new AI tool from Northeastern University can map AML genetic mutations to potentially reduce diagn…
A new AI tool from Northeastern University can map AML genetic mutations to potentially reduce diagnosis-to-treatment time, while a study warns that some AI pathology models may use unreliable 'shortcut learning.' Separately, an AI blood test developed in Taiwan, PanMETAI, detects early-stage pancreatic cancer with over 90% accuracy.
Researchers at Fred Hutch Cancer Center are testing a collaborative AI research platform designed to…
Researchers at Fred Hutch Cancer Center are testing a collaborative AI research platform designed to accelerate cancer research and develop AI models for predicting cancer progression, treatment effectiveness, and resistance mechanisms. The platform uses de-identified clinical data from member institutions to train these models, aiming for faster diagnoses and more precise therapies, particularly for rare cancers, while safeguarding patient privacy.
Researchers have developed AI-designed molecular sensors for early cancer detection, with potential for at-home urine tests.
Researchers have developed AI-designed molecular sensors for early cancer detection, with potential for at-home urine tests. The FDA granted breakthrough designation to PathAI's AI-powered dermatopathology solution, PathAssist Derm. However, new research suggests some AI pathology tools may rely on 'shortcut learning,' raising concerns about their reliability.
Researchers at MIT and Microsoft have developed AI-designed molecular sensors for early cancer detection, with potential for home use.
Researchers at MIT and Microsoft have developed AI-designed molecular sensors for early cancer detection, with potential for home use. PathAI received FDA breakthrough designation for its AI-powered dermatopathology solution, PathAssist Derm. Additionally, a new AI tool from Northeastern University can map AML genetic mutations and predict drug resistance, aiming to significantly reduce diagnosis-to-treatment time.
The FDA has granted pre-market approval to Claire, the first AI-imaging device in the U.
The FDA has granted pre-market approval to Claire, the first AI-imaging device in the U.S. for intraoperative breast cancer margin assessment during surgery. Separately, an Australian AI tool named BRAIx has shown higher accuracy than traditional factors in predicting breast cancer risk within four years using mammograms.
An Australian AI-based tool, BRAIx, can now predict a woman's breast cancer risk within four years using mammograms with higher accuracy than traditional factors.
An Australian AI-based tool, BRAIx, can now predict a woman's breast cancer risk within four years using mammograms with higher accuracy than traditional factors. Separately, Vanderbilt Health and Bertis have formed a collaboration to advance cancer drug discovery using AI-driven proteomics and molecular AI initiatives.
Show earlier developments (97 more)
Australian research indicates an AI-based tool, BRAIx, can predict a woman's risk of developing brea…
Australian research indicates an AI-based tool, BRAIx, can predict a woman's risk of developing breast cancer within the next four years using mammograms with higher accuracy than traditional factors. A world-first trial in Sweden has shown that AI can help doctors identify more breast cancer cases during routine screenings by analyzing mammograms and flagging abnormalities. However, new research suggests many AI cancer pathology tools may rely on 'shortcut learning' rather than genuine biological signals, raising concerns about their reliability.
PathAI received U.
PathAI received U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI tool designed to analyze skin lesions. LG CNS is expanding its AI applications in the pharmaceutical and digital health sectors, investing in CHA Biotech and developing an AI-based clinical trial design platform. These advancements aim to accelerate drug development and improve diagnostic workflows.
Perimeter Medical Imaging AI's 'Claire' has become the first FDA-approved AI-enabled imaging device for breast cancer surgery.
Perimeter Medical Imaging AI's 'Claire' has become the first FDA-approved AI-enabled imaging device for breast cancer surgery. The device uses AI and wide-field OCT imaging for real-time evaluation of excised tumor margins. The pivotal trial demonstrated an 88.1% margin accuracy and a statistically significant reduction in patients with residual cancer post-surgery.
Vanderbilt Health and Bertis have launched a collaboration to advance cancer drug discovery by integrating proteomics and AI.
Vanderbilt Health and Bertis have launched a collaboration to advance cancer drug discovery by integrating proteomics and AI. A new AI tool from Northeastern University aims to drastically reduce acute myeloid leukemia (AML) diagnosis and treatment planning time from weeks to a single night by mapping genetic mutations. Additionally, research from the University of Warwick highlights concerns that AI pathology models may rely on 'shortcut learning,' potentially leading to unreliable predictions in patient care.
Northeastern University researcher Kiran Vanaja has developed a new AI tool designed to significantly reduce treatment determination time for acute myeloid leukemia (AML).
Northeastern University researcher Kiran Vanaja has developed a new AI tool designed to significantly reduce treatment determination time for acute myeloid leukemia (AML). The tool can diagnose AML, map genetic mutations, suggest potential drugs, and predict drug resistance, potentially cutting the time from diagnosis to treatment from weeks to a single night.
New research indicates an AI pipeline using large language models can accurately predict the future …
New research indicates an AI pipeline using large language models can accurately predict the future risk of advanced neoplasia in patients with colitis-associated low-grade dysplasia. Separately, research from the University of Warwick warns that many AI tools for cancer pathology may rely on 'shortcut learning' rather than genuine biological signals, potentially impacting diagnostic reliability.
PathAI announced its AI-powered pathology solution, PathAssist Derm, received U.
PathAI announced its AI-powered pathology solution, PathAssist Derm, received U.S. FDA Breakthrough Device Designation for analyzing skin lesions. Separately, research highlights concerns that AI pathology tools may use 'shortcut learning' rather than genuine biological signals, potentially impacting reliability. AI is also transforming drug development, with AI-enabled discovery workflows projected to reduce early timelines by up to 40% and costs by 30%.
Generate:Biomedicines has completed a $425 million IPO on the Nasdaq to advance AI-powered drug deve…
Generate:Biomedicines has completed a $425 million IPO on the Nasdaq to advance AI-powered drug development, with CEO Mike Nally emphasizing biology's role in unlocking AI's potential. Northeastern University has developed a patented AI tool that can diagnose acute myeloid leukemia, map its genetic mutations, and suggest treatments, potentially reducing diagnosis-to-treatment time from weeks to a single night.
Vanderbilt Health and Bertis have launched a collaboration to advance AI, spatial biology, and translational cancer research for drug discovery.
Vanderbilt Health and Bertis have launched a collaboration to advance AI, spatial biology, and translational cancer research for drug discovery. Northeastern University has developed a new AI tool that can diagnose acute myeloid leukemia, map its genetic mutations, and predict drug resistance, potentially reducing diagnosis-to-treatment time. Additionally, MD Anderson Cancer Center will host a discussion on the responsible implementation of AI innovations in oncology.
Researchers have developed AI-generated sensors using peptides and nanoparticles that can detect spe…
Researchers have developed AI-generated sensors using peptides and nanoparticles that can detect specific cancer types based on protease markers, potentially enabling simple at-home urine tests. Scientists are also using AI to design custom proteins that guide immune cells to target cancer, a promising form of immunotherapy. Additionally, an AI algorithm can now automate the detection of rare cancer cells in blood samples within approximately 10 minutes, significantly speeding up liquid biopsy processes.
Researchers have developed AI-generated sensors using peptides and nanoparticles for earlier cancer …
Researchers have developed AI-generated sensors using peptides and nanoparticles for earlier cancer detection, potentially identifying specific cancer types based on protease markers. A new study warns that many AI cancer diagnostic tools may rely on 'shortcut learning' rather than genuine biological signals, raising concerns about their reliability for patient care.
Scientists have used AI to design custom proteins that guide immune cells to target cancer cells, showing promise in immunotherapy.
Scientists have used AI to design custom proteins that guide immune cells to target cancer cells, showing promise in immunotherapy. A new AI system can recommend cancer treatments based on tumor genetics with over 90% accuracy compared to expert clinicians. However, research also warns that some AI cancer tools may rely on 'shortcut learning' rather than true biological signals, potentially impacting reliability.
Merck Sharp & Dohme (MSD) is using AI models TEDDY and KERMT to accelerate drug design, doubling their promising drug candidates with two new molecules entering clinical trials.
Merck Sharp & Dohme (MSD) is using AI models TEDDY and KERMT to accelerate drug design, doubling their promising drug candidates with two new molecules entering clinical trials. Researchers at USC have developed an AI algorithm that automates the detection of rare cancer cells in blood samples via liquid biopsy, identifying cancer cells in approximately 10 minutes. UCLA researchers created an AI tool, AQuA, to detect errors in digital pathology images, achieving 99.8% accuracy.
Generate Biomedicines, an AI-driven drug developer, has raised $400 million through its U.
Generate Biomedicines, an AI-driven drug developer, has raised $400 million through its U.S. initial public offering to advance its platform for protein-based therapeutics. Concurrently, Jeeva Clinical Trials is urging the life sciences industry to modernize infrastructure to fully leverage AI in drug development, emphasizing that unified systems are crucial for AI's effectiveness.
Artificial intelligence is being integrated into healthcare in Estonia for diagnostics in neurology, pathology, and ophthalmology.
Artificial intelligence is being integrated into healthcare in Estonia for diagnostics in neurology, pathology, and ophthalmology. A review highlights AI's promise in improving oral cancer diagnosis, while Roche is leveraging AI and machine learning to accelerate drug discovery timelines and reduce costs.
Clearnote Health has launched its enhanced Avantect Pancreatic Cancer Test, an AI-powered blood test designed to detect pancreatic cancer in high-risk individuals.
Clearnote Health has launched its enhanced Avantect Pancreatic Cancer Test, an AI-powered blood test designed to detect pancreatic cancer in high-risk individuals. The test analyzes blood samples for cancer-related molecules, using AI models to calculate a patient's risk level. In high-risk patients, the Avantect test shows an 82.6% sensitivity and 97.5% specificity for cancer detection.
Researchers have developed AI models to design molecular sensors for early cancer detection, potentially detectable through urine tests.
Researchers have developed AI models to design molecular sensors for early cancer detection, potentially detectable through urine tests. Additionally, AI is being used to design proteins that guide cancer-fighting immune cells, and AI assistance has been shown to improve the detection of cancers on digital breast tomosynthesis images. Biorce also secured $52.5 million in Series A funding to advance its AI technology for clinical trials.
UC San Diego researchers have developed a new AI tool that precisely maps the urethra on MRI scans t…
UC San Diego researchers have developed a new AI tool that precisely maps the urethra on MRI scans to improve the safety and reduce urinary side effects of prostate cancer radiation therapy. The AI tool demonstrated performance comparable to or exceeding human experts, accurately identifying 81% of the true urethra compared to 34% by physicians in testing.
WuXi XDC and Earendil Labs have entered a strategic collaboration potentially valued at $885 million…
WuXi XDC and Earendil Labs have entered a strategic collaboration potentially valued at $885 million, combining WuXi XDC's antibody-drug conjugate (ADC) technology with Earendil's AI-driven antibody discovery platform. Earendil will license WuXi XDC's proprietary WuXiTecan-2 payload-linker technology to develop ADC candidates for cancer and autoimmune diseases. This partnership aims to accelerate the development of next-generation ADCs by leveraging Earendil's AI capabilities for antibody discovery.
Researchers are exploring AI-based tools to identify women at higher risk for breast cancer, potenti…
Researchers are exploring AI-based tools to identify women at higher risk for breast cancer, potentially detecting cancers missed by standard mammograms by analyzing subtle imaging features. Additionally, AI models are being developed to design molecular sensors for early cancer detection through urine tests and to guide cancer-fighting immune cells to target cancer cells more effectively.
Northwell Health has developed an AI clinical tool named iNav that significantly accelerates the detection and treatment of pancreatic cancer.
Northwell Health has developed an AI clinical tool named iNav that significantly accelerates the detection and treatment of pancreatic cancer. A study published in The Oncologist revealed that iNav can cut the time from biopsy to diagnosis in half, from 12 days to six days, and also reduced the wait time for an oncologist appointment and treatment initiation.
Researchers have developed an AI system called MAGIC to track genetic mishaps within living cells th…
Researchers have developed an AI system called MAGIC to track genetic mishaps within living cells that may lead to cancer, combining microscopy, AI image analysis, and genomic sequencing. Additionally, AI models are being used to design molecular sensors for early cancer detection via at-home urine tests. Labcorp is also expanding its collaboration with PathAI to deploy an AI-powered digital pathology platform across its U.S. labs.
An international team of scientists has developed a new method using AI and 3D technology to improve the detection of cancer cells, particularly for cervical cancer.
An international team of scientists has developed a new method using AI and 3D technology to improve the detection of cancer cells, particularly for cervical cancer. This AI-driven approach automates the analysis of cervical cell samples, offering a more precise and efficient alternative to traditional methods like the Pap smear test. The method promises to revolutionize cervical cancer diagnosis by accelerating the process and potentially leading to earlier life-saving treatment.
Researchers have developed an electronic nose utilizing machine learning and AI to detect early sign…
Researchers have developed an electronic nose utilizing machine learning and AI to detect early signs of ovarian cancer from blood samples, a method that could be adapted for various cancers. Additionally, an AI-based tool is being investigated at UMass Chan Medical School to identify women at higher risk for breast cancer by analyzing subtle imaging features missed by standard mammograms.
Generative AI has demonstrated the ability to process vast medical datasets significantly faster than human research teams, potentially yielding stronger results.
Generative AI has demonstrated the ability to process vast medical datasets significantly faster than human research teams, potentially yielding stronger results. In Australia, AI is poised to offer productivity gains in pathology, including augmented diagnostics and faster turnaround times for complex testing. Furthermore, an AI-powered electronic nose has achieved 97% accuracy in detecting early signs of ovarian cancer from blood samples.
Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. has increased its financing to approximately CA$2.0 million to advance its AI-driven cancer drug programs. The company's collaboration with NanoPalm combines Rakovina's AI-enabled drug discovery with NanoPalm's delivery platform. Planned milestones for 2026 include joint venture funding and pursuing partnerships for antibody drug conjugate payloads.
iCAD's ProFound AI Suite, a new AI-powered mammogram technology, has demonstrated a 23% increase in cancer detection rates and a reduction in false positives.
iCAD's ProFound AI Suite, a new AI-powered mammogram technology, has demonstrated a 23% increase in cancer detection rates and a reduction in false positives. Radiologist Dr. Kenneth Meng stated that AI is revolutionizing mammography and early breast cancer detection. The AI tool analyzes mammograms to highlight suspicious areas and reassure radiologists about benign regions, with a study involving over 100,000 breast imaging exams.
Caris has launched a proprietary AI Insights Signature that uses AI and machine learning to better understand patient responses to oral chemotherapy drugs for breast cancer.
Caris has launched a proprietary AI Insights Signature that uses AI and machine learning to better understand patient responses to oral chemotherapy drugs for breast cancer. Researchers at IIT Indore have developed an AI system that analyzes medical images to improve early detection of breast and cervical cancer, identifying suspicious areas and reducing missed diagnoses. A study published in the Journal of the American College of Radiology indicates that AI assistance significantly increases cancer detection rates on screening digital breast tomosynthesis images, leading to a nearly 22% rise in detection.
Researchers have developed AI models to create molecular sensors for early cancer detection, potentially enabling at-home urine tests for lung, ovarian, and colon cancers.
Researchers have developed AI models to create molecular sensors for early cancer detection, potentially enabling at-home urine tests for lung, ovarian, and colon cancers. AI has also been utilized to design new molecules with potential antitumor activity, identifying compounds that show significant cytotoxic activity against tumor cells. Additionally, advanced AI systems are being developed to rapidly analyze medical images for improved early detection of breast and cervical cancer.
Epredia and Mindpeak have entered into a distribution agreement to offer Mindpeak's AI image recogni…
Epredia and Mindpeak have entered into a distribution agreement to offer Mindpeak's AI image recognition software to Epredia's digital pathology customers in the European Union, aiming to enhance precision and speed in diagnostic image review. Concurrently, a review highlights the integration of AI and machine learning with chemoinformatics to identify and validate natural products for treating cancer metastasis and chemoresistance.
Researchers have developed AI-generated sensors using peptides that can signal the presence of cance…
Researchers have developed AI-generated sensors using peptides that can signal the presence of cancer-linked proteases, potentially leading to at-home urine tests for early cancer detection. Additionally, an AI-powered electronic nose can detect early signs of ovarian cancer in blood samples with 97% accuracy by analyzing volatile substances emitted by cancer cells.
AI assistance in digital breast tomosynthesis (DBT) has shown an increase in detecting invasive and lobular cancers, as well as smaller tumors.
AI assistance in digital breast tomosynthesis (DBT) has shown an increase in detecting invasive and lobular cancers, as well as smaller tumors. Researchers have also developed AI-generated sensors that can detect cancer-linked proteases, paving the way for early-stage detection through simple urine tests. Additionally, a new AI-based tool from MIT can rapidly annotate medical images, potentially accelerating clinical research.
Labcorp announced an expanded collaboration with PathAI to deploy the FDA-cleared AISight® Dx digita…
Labcorp announced an expanded collaboration with PathAI to deploy the FDA-cleared AISight® Dx digital pathology platform across its national network of labs and hospital collaborations. This platform utilizes AI to support diagnostic processes, enhance case management, and improve slide review and collaboration. The expansion includes AI-driven clinical trial support.
A real-world study found that AI tools, used with 3D mammography across four sites, increased cancer…
A real-world study found that AI tools, used with 3D mammography across four sites, increased cancer detection rates by nearly 22% among breast radiologists without raising false positives. Telefónica, Fundación Vithas, and Francisco de Vitoria University are pioneering a project using quantum computing and AI to design cancer drugs targeting the BRAF V600E mutation, showing preliminary results of improved molecular candidates. Additionally, AI is being used to design proteins that act as a 'GPS' for T cells to more effectively locate and target cancer cells.
Researchers have developed a new AI 'fingerprint' technology that analyzes changes in cancer cell sh…
Researchers have developed a new AI 'fingerprint' technology that analyzes changes in cancer cell shape to assess drug responses, potentially halving cancer drug development time with up to 99.3% accuracy. Additionally, a low-cost AI model can screen cervical cancer samples in 30 seconds, and human-AI teams have shown improved accuracy in identifying eligible patients for cancer clinical trials.
A study published on February 20 in the Journal of the American College of Radiology indicates that …
A study published on February 20 in the Journal of the American College of Radiology indicates that AI assistance significantly improves the detection of invasive and lobular cancers on screening digital breast tomosynthesis (DBT) images. The AI-enhanced interpretation led to the identification of more small-sized cancers, particularly in dense breasts.
Evogene and Queensland University of Technology (QUT) have partnered to accelerate the discovery of …
Evogene and Queensland University of Technology (QUT) have partnered to accelerate the discovery of AI-driven small molecule cancer therapeutics, focusing on overcoming resistance to chemotherapy and targeted therapies. Insilico Medicine and Eli Lilly have also published a vision for fully autonomous "Prompt-to-Drug" pharmaceutical R&D, outlining how AI can streamline the entire drug discovery pipeline.
Researchers at the University of Maine have developed a new AI tool called the Context-Guided Segmen…
Researchers at the University of Maine have developed a new AI tool called the Context-Guided Segmentation Network (CGS-Net) to enhance early breast cancer detection by analyzing digital breast tissue images and considering surrounding tissue for a more comprehensive analysis. Pathology News also highlights recent developments in AI-enhanced imaging for cancer detection and new digital pathology methods, focusing on improving accuracy and efficiency in analyzing tissue samples.
An international research team has developed M-PACT, a new AI-based analysis method that accurately …
An international research team has developed M-PACT, a new AI-based analysis method that accurately classifies brain tumors and monitors disease progression using genetic material from cerebrospinal fluid. The tool analyzes cell-free DNA fragments to identify characteristic molecular patterns for tumor classification. This development was reported on February 20, 2026.
Isomorphic Labs, an Alphabet company, has launched its AI-driven IsoDDE engine, a significant advancement in cancer drug discovery.
Isomorphic Labs, an Alphabet company, has launched its AI-driven IsoDDE engine, a significant advancement in cancer drug discovery. This engine reportedly achieves double the accuracy of AlphaFold 3 in predicting protein-ligand structures and surpasses traditional methods in predicting binding affinity. Furthermore, IsoDDE can identify previously hidden binding pockets on proteins solely from their amino acid sequences, a capability that previously required extensive experimental work.
Researchers at the University of Arizona are collaborating with Quantoom Biosciences to develop an AI and mRNA-based framework for personalized cancer vaccines.
Researchers at the University of Arizona are collaborating with Quantoom Biosciences to develop an AI and mRNA-based framework for personalized cancer vaccines. This platform will identify neoantigen candidates to train the immune system against mutated tumor proteins. Separately, Stanford Medicine has developed Nuclei.io, an AI tool that enhances the speed and accuracy of pathologists in identifying cells, which is crucial for clinical trial enrollment, particularly in cancer.
The PANORAMA study has shown that an AI system achieved a higher diagnostic performance than radiologists in detecting pancreatic cancer on CT scans, with an AUROC of 0.
The PANORAMA study has shown that an AI system achieved a higher diagnostic performance than radiologists in detecting pancreatic cancer on CT scans, with an AUROC of 0.92 compared to the radiologists' pooled performance of 0.88. The AI detected 38% more cancers at matched specificity and reduced false positives by 26% at matched sensitivity, suggesting it can augment radiologist capabilities.
Evogene and Queensland University of Technology (QUT) have announced a collaboration to develop AI-driven small molecule cancer therapeutics.
Evogene and Queensland University of Technology (QUT) have announced a collaboration to develop AI-driven small molecule cancer therapeutics. This partnership will focus on therapy-resistant non-small cell lung cancer (NSCLC) and other cancers, utilizing Evogene's ChemPass AI platform to generate and prioritize potential drug candidates.
Insilico Medicine has partnered with Memorial Sloan Kettering Cancer Center (MSK) to discover novel therapeutic targets for gastroesophageal cancers.
Insilico Medicine has partnered with Memorial Sloan Kettering Cancer Center (MSK) to discover novel therapeutic targets for gastroesophageal cancers. This collaboration will integrate MSK's clinical data with Insilico's AI-driven drug development platform to advance treatment strategies.
Bristol Myers Squibb is implementing Evinova's AI-enabled clinical development platform globally to enhance trial design and accelerate timelines.
Bristol Myers Squibb is implementing Evinova's AI-enabled clinical development platform globally to enhance trial design and accelerate timelines. Evogene and Queensland University of Technology (QUT) are collaborating to advance AI-driven cancer therapeutics, focusing on chemotherapy and targeted therapy-resistant non-small cell lung cancer.
Johns Hopkins Medicine researchers are employing AI to expedite and refine cancer drug discovery, aiming for a faster, more precise, and cost-effective process.
Johns Hopkins Medicine researchers are employing AI to expedite and refine cancer drug discovery, aiming for a faster, more precise, and cost-effective process. Scientists have created an AI system that designs custom proteins to guide cancer-fighting immune cells more effectively. Additionally, MIT chemical engineers have developed a new AI model that optimizes protein manufacturing processes in industrial yeasts, potentially lowering the cost of protein drug development.
In AI drug development, Thermo Fisher Scientific's PPD has partnered with Datavant to enhance real-world data integration in clinical research.
In AI drug development, Thermo Fisher Scientific's PPD has partnered with Datavant to enhance real-world data integration in clinical research. Evogene is expanding its alliance with Google Cloud to integrate AI agents. Additionally, Lantern Pharma showcased its ZETA AI platform, demonstrating its capability to design new cancer drugs by analyzing vast datasets.
Scientists have developed a new AI-powered blood test capable of detecting brain cancer with approximately 75% accuracy by analyzing DNA and immune system signals.
Scientists have developed a new AI-powered blood test capable of detecting brain cancer with approximately 75% accuracy by analyzing DNA and immune system signals. Additionally, an updated AI blood test, DELFI, can now detect liver cancer with over 80% accuracy, including in its early stages.
Dr. Regina Barzilay, an MIT professor, has developed an AI model named MIRAI capable of predicting a…
Dr. Regina Barzilay, an MIT professor, has developed an AI model named MIRAI capable of predicting a patient's risk of developing breast cancer within five years. The model excels at identifying subtle changes in mammograms that are difficult for human eyes to discern, advancing early cancer detection capabilities.
Takeda Pharmaceutical has entered into a significant partnership with Iambic Therapeutics, aiming to utilize artificial intelligence for drug discovery in cancer and other diseases.
Takeda Pharmaceutical has entered into a significant partnership with Iambic Therapeutics, aiming to utilize artificial intelligence for drug discovery in cancer and other diseases. This collaboration grants Takeda access to Iambic's AI-driven platform and a predictive model for protein-receptor interactions. The deal has a potential value exceeding $1.7 billion.
Researchers have developed AI models for designing peptides that act as sensors for cancer-linked proteases, potentially enabling early detection anywhere in the body.
Researchers have developed AI models for designing peptides that act as sensors for cancer-linked proteases, potentially enabling early detection anywhere in the body. Additionally, a new AI algorithm automates the detection of rare cancer cells in blood samples for liquid biopsies, significantly reducing analysis time. Johns Hopkins Medicine is also advancing cancer care with AI-based liquid biopsies showing promise for early detection of brain and liver cancers.
New research indicates AI-assisted mammography can significantly improve the early detection of aggressive breast cancers, reducing interval and aggressive cancer rates.
New research indicates AI-assisted mammography can significantly improve the early detection of aggressive breast cancers, reducing interval and aggressive cancer rates. Additionally, AI-generated sensors using peptides are being developed for early cancer detection by signaling the presence of cancer-linked proteases. Advances in AI-based liquid biopsies and blood tests also show promise for detecting brain and liver cancers, respectively.
GV20 Therapeutics has utilized AI to discover and develop a new antibody drug, GV20-0251, which targets a novel immune checkpoint, IGSF8.
GV20 Therapeutics has utilized AI to discover and develop a new antibody drug, GV20-0251, which targets a novel immune checkpoint, IGSF8. This drug showed promising results in a phase one clinical trial for advanced solid tumors, helping to shrink tumors or stabilize disease progression.
A new multimodal artificial intelligence model has demonstrated superior accuracy in predicting breast cancer recurrence compared to the Oncotype DX genomic test.
A new multimodal artificial intelligence model has demonstrated superior accuracy in predicting breast cancer recurrence compared to the Oncotype DX genomic test. This AI model integrates molecular, histopathologic, and clinical data from patients to provide more precise recurrence risk scores for HR-positive, HER2-negative breast cancer.
Generative AI is showing significant promise in revolutionizing drug discovery by accelerating timel…
Generative AI is showing significant promise in revolutionizing drug discovery by accelerating timelines and reducing failure rates, particularly in designing antibody candidates for previously undruggable targets. Additionally, researchers are utilizing AI to design molecular sensors for early cancer detection, aiming to identify the disease in its initial stages.
Investigators from Mass General Brigham have developed a new AI foundation model named BrainIAC.
Investigators from Mass General Brigham have developed a new AI foundation model named BrainIAC. This tool can extract multiple disease risk signals from routine brain MRIs, enabling it to estimate brain age, predict dementia risk, detect brain tumor mutations, and forecast cancer survival rates.
New research suggests that AI-assisted mammograms can enhance the early detection of breast cancers and decrease the occurrence of interval diagnoses.
New research suggests that AI-assisted mammograms can enhance the early detection of breast cancers and decrease the occurrence of interval diagnoses. A study involving 100,000 women in Sweden found that AI-supported screening led to fewer aggressive or advanced cancers being diagnosed between screenings.
An AI algorithm has demonstrated the ability to predict outcomes for oropharyngeal carcinoma by identifying extranodal extension (ENE) from CT scans.
An AI algorithm has demonstrated the ability to predict outcomes for oropharyngeal carcinoma by identifying extranodal extension (ENE) from CT scans. A study involving over 1,700 patients found that the number of ENE nodes detected by AI was significantly associated with overall survival and disease control. This application of AI offers a powerful biomarker for assessing patient prognosis.
A large trial in Sweden suggests AI can significantly improve breast cancer screening, leading to a 12% reduction in interval cancers and better detection of aggressive subtypes.
A large trial in Sweden suggests AI can significantly improve breast cancer screening, leading to a 12% reduction in interval cancers and better detection of aggressive subtypes. Additionally, Norwegian hospitals are implementing AI diagnostic tools like PROVIZ for prostate cancer, enabling quicker and more accurate assessments.
The UK has launched its National Cancer Plan, which will prioritize technology, data, and AI with substantial investment to enhance cancer care.
The UK has launched its National Cancer Plan, which will prioritize technology, data, and AI with substantial investment to enhance cancer care. The plan includes a transition to digital and robotic automation for histopathology, aiming for significant productivity gains.
ConcertAI has launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform aimed at automating and optimizing the entire clinical trial lifecycle.
ConcertAI has launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform aimed at automating and optimizing the entire clinical trial lifecycle. Unveiled at SCOPE 2026, ACT integrates real-world data with advanced AI workflows to potentially shorten trial timelines by 10 to 20 months and reduce costs.
BostonGene has announced a significant independent validation of its AI and machine learning capabilities for assessing HER2 expression in breast cancer.
BostonGene has announced a significant independent validation of its AI and machine learning capabilities for assessing HER2 expression in breast cancer. A blinded, multi-vendor HER2 benchmarking study showed high agreement rates for BostonGene's foundation model, as published in Modern Pathology.
Massive Bio introduced its AI-based TrialRelay platform at the SCOPE 2026 conference, designed to prevent patient loss during oncology clinical trial referrals.
Massive Bio introduced its AI-based TrialRelay platform at the SCOPE 2026 conference, designed to prevent patient loss during oncology clinical trial referrals.
The FDA granted several critical designations for novel cancer therapies, including an orphan drug d…
The FDA granted several critical designations for novel cancer therapies, including an orphan drug designation for an AI-related imaging agent for pancreatic cancer, highlighting the ongoing shift towards precision medicine.
The AI cancer diagnostics market in Asia Pacific is projected to grow from $41.
The AI cancer diagnostics market in Asia Pacific is projected to grow from $41.7 million in 2023 to $247.4 million by 2030, with 80% of FDA-approved AI oncology devices focusing on diagnostics.
A new AI algorithm has been invented to automatically detect rare cancer cells in blood samples within approximately 10 minutes, a crucial step for liquid biopsies.
A new AI algorithm has been invented to automatically detect rare cancer cells in blood samples within approximately 10 minutes, a crucial step for liquid biopsies. Additionally, a large trial in Sweden found that using AI in breast cancer screening reduced the rate of later diagnosis by 12% and increased early detection rates.
The NHS has launched a pioneering pilot program that uses AI and robotic technology to detect lung cancer earlier, complementing an expanded screening initiative.
The NHS has launched a pioneering pilot program that uses AI and robotic technology to detect lung cancer earlier, complementing an expanded screening initiative. This new approach employs AI software to rapidly analyze lung scans and identify potentially cancerous lumps.
Pharmaceutical companies are increasingly leveraging AI to streamline clinical trials and accelerate regulatory submissions, optimizing time-consuming processes in drug development.
Pharmaceutical companies are increasingly leveraging AI to streamline clinical trials and accelerate regulatory submissions, optimizing time-consuming processes in drug development. This application focuses on improving efficiency rather than new molecule discovery.
The FDA and EMA jointly issued Good AI Practice principles for drug development, establishing regulatory expectations for responsible AI use in pharmaceuticals.
The FDA and EMA jointly issued Good AI Practice principles for drug development, establishing regulatory expectations for responsible AI use in pharmaceuticals.
Researchers have developed AI models to design peptides for sensors that detect cancer early and custom proteins to guide immune cells to target cancer cells more effectively.
Researchers have developed AI models to design peptides for sensors that detect cancer early and custom proteins to guide immune cells to target cancer cells more effectively. Additionally, AI is revolutionizing clinical trials by accelerating drug development, improving patient recruitment, and reducing trial failures through tools like causal inference and digital twins.
Researchers have developed AI-generated molecular sensors for early cancer detection via urine tests and an AI tool to automate cancer cell detection in blood samples.
Researchers have developed AI-generated molecular sensors for early cancer detection via urine tests and an AI tool to automate cancer cell detection in blood samples. A study also found that AI significantly improves cancer detection rates for breast radiologists. These advancements aim to enhance early diagnosis and treatment of various cancers.
Researchers have developed AI-designed peptide sensors for early cancer detection via urine tests, a…
Researchers have developed AI-designed peptide sensors for early cancer detection via urine tests, and generative AI is now processing complex medical datasets significantly faster than human experts. Additionally, Jeeva Clinical Trials is urging the life sciences industry to modernize infrastructure to fully leverage AI in drug development, emphasizing the need for unified systems and regulatory compliance.
Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests for various cancers.
Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests for various cancers. Separately, MIT chemical engineers created a new AI model that optimizes protein manufacturing processes, potentially reducing costs for cancer-treating drugs like monoclonal antibodies.
Researchers have created an AI model capable of designing peptides that can act as sensors for cancer-specific proteases.
Researchers have created an AI model capable of designing peptides that can act as sensors for cancer-specific proteases. These peptides, when incorporated into nanoparticles, can detect the presence of these overactive enzymes throughout the body. This breakthrough holds promise for developing new methods for early cancer detection, potentially even for at-home use.
MIT and Microsoft researchers developed an AI model to design molecular sensors for early cancer detection, potentially leading to at-home urine tests.
MIT and Microsoft researchers developed an AI model to design molecular sensors for early cancer detection, potentially leading to at-home urine tests.
City of Hope experts predicted that by 2026, AI will be an integrated driver of improved patient care, with digital pathology and multi-omics AI becoming standard.
City of Hope experts predicted that by 2026, AI will be an integrated driver of improved patient care, with digital pathology and multi-omics AI becoming standard.
Microsoft Research developed GigaTIME, a new AI platform that accelerates cancer research by analyzi…
Microsoft Research developed GigaTIME, a new AI platform that accelerates cancer research by analyzing pathology slides to create detailed digital maps of tumor environments and reveal immune cell interactions.
Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to target and destroy cancer cells.
Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to target and destroy cancer cells. Russian researchers have also created a neural network capable of detecting early-stage breast cancer from CT scans in minutes, reducing clinical error probability by approximately 20%.
Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to targets and killing melanoma cells in lab experiments.
Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to targets and killing melanoma cells in lab experiments. Stanford Medicine developed an AI tool, Nuclei.io, to enhance pathologists' efficiency and diagnostic accuracy by rapidly identifying specific cells in biopsy samples. A trial in Sweden showed AI can help doctors identify more breast cancer cases during routine screenings by analyzing mammograms.
Scientists have utilized AI tools, including generative AI model RFdiffusion, to design custom proteins that act as a "GPS" for cancer-fighting immune cells.
Scientists have utilized AI tools, including generative AI model RFdiffusion, to design custom proteins that act as a "GPS" for cancer-fighting immune cells. These AI-designed proteins, when engineered onto T cells, have shown the ability to rapidly kill melanoma cells in lab experiments. This approach represents a new method for utilizing AI in cancer treatment.
Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests.
Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests. Separately, a novel AI model named ECgMPL has demonstrated near 100% accuracy in identifying endometrial cancer and can be adapted for other cancer types. Additionally, a new AI algorithm called RED can automate the detection of rare cancer cells in blood samples within 10 minutes.
A new AI model, ECgMPL, has demonstrated 99.
A new AI model, ECgMPL, has demonstrated 99.26% accuracy in identifying endometrial cancer from microscopic images, significantly surpassing human diagnostic capabilities. Additionally, an AI system named AQuA has been developed to detect errors in digital pathology images with 99.8% accuracy. AI-assisted mammography trials suggest a reduction in aggressive breast cancer detection rates.
Insilico Medicine announced a breakthrough with AI-designed CDK12/13 inhibitors showing promise against treatment-resistant cancers, moving towards clinical trials.
Insilico Medicine announced a breakthrough with AI-designed CDK12/13 inhibitors showing promise against treatment-resistant cancers, moving towards clinical trials.
Researchers at UChicago Medicine received significant funding to use AI and supercomputing to identify new targets for drug-resistant cancer therapies.
Researchers at UChicago Medicine received significant funding to use AI and supercomputing to identify new targets for drug-resistant cancer therapies.
A new AI tool (CHIEF) achieved nearly 94% accuracy in cancer detection, guided treatment, and predicted patient survival across multiple cancer types.
A new AI tool (CHIEF) achieved nearly 94% accuracy in cancer detection, guided treatment, and predicted patient survival across multiple cancer types.
The FDA has cleared ArteraAI Breast, an AI-based digital pathology tool for early-stage breast cancer risk stratification.
The FDA has cleared ArteraAI Breast, an AI-based digital pathology tool for early-stage breast cancer risk stratification. Recursion announced progress in its AI-driven drug discovery platform. New AI tools, SPARK and STimage, have been developed for analyzing tissue sections and detecting hidden cancer markers, respectively. The REDMOD AI model continues to show potential in detecting pancreatic cancer up to three years before clinical diagnosis.
The National Cancer Institute (NCI) reported using AI to improve cervical and prostate cancer screening, and for drug repurposing and predicting patient responses to treatment.
The National Cancer Institute (NCI) reported using AI to improve cervical and prostate cancer screening, and for drug repurposing and predicting patient responses to treatment.
Roche is establishing a large-scale AI factory to accelerate drug development, with early results showing AI designing an oncology treatment molecule 25% faster.
Roche is establishing a large-scale AI factory to accelerate drug development, with early results showing AI designing an oncology treatment molecule 25% faster. Ibex Medical Analytics has launched a new AI-powered pathology platform, Ibex 4, to assist with breast cancer biopsy analysis. Additionally, Spotlight Pathology secured £1.4 million to commercialize its AI tools for blood cancer diagnosis, and regulatory bodies like the EMA and FDA have published principles for the responsible use of AI in drug development.
Research demonstrated AI's capability to predict pancreatic cancer incidence from patient records, offering a less invasive and potentially more accurate screening method.
Research demonstrated AI's capability to predict pancreatic cancer incidence from patient records, offering a less invasive and potentially more accurate screening method.
A study highlighted AI's critical role in precision medicine, enabling personalized treatment plans and predicting treatment effects for cancer patients based on genomic data.
A study highlighted AI's critical role in precision medicine, enabling personalized treatment plans and predicting treatment effects for cancer patients based on genomic data.
The Advanced Research Projects Agency for Health (ARPA-H) was established, later becoming a key funder for AI projects in cancer research.
The Advanced Research Projects Agency for Health (ARPA-H) was established, later becoming a key funder for AI projects in cancer research.
Evotec and Exscientia announced an AI-developed oncology candidate entering Phase 1 clinical trials, significantly accelerating the drug discovery timeline.
Evotec and Exscientia announced an AI-developed oncology candidate entering Phase 1 clinical trials, significantly accelerating the drug discovery timeline.
Google's deep learning system demonstrated superior performance over radiologists in breast cancer screening, reducing false positives and negatives.
Google's deep learning system demonstrated superior performance over radiologists in breast cancer screening, reducing false positives and negatives.
Exscientia showcased AI's potential by developing a preclinical drug candidate in significantly less time than traditional methods, highlighting accelerated drug discovery.
Exscientia showcased AI's potential by developing a preclinical drug candidate in significantly less time than traditional methods, highlighting accelerated drug discovery.
AI applications in cancer imaging demonstrated effectiveness in screening for lung nodules on low-dose CT scans, contributing to earlier diagnoses.
AI applications in cancer imaging demonstrated effectiveness in screening for lung nodules on low-dose CT scans, contributing to earlier diagnoses.
AI-powered automated segmentation techniques were developed, improving reproducibility and efficiency in tumor analysis for treatment planning.
AI-powered automated segmentation techniques were developed, improving reproducibility and efficiency in tumor analysis for treatment planning.
Recursion Pharmaceuticals was founded with the vision of utilizing AI to understand cellular biology…
Recursion Pharmaceuticals was founded with the vision of utilizing AI to understand cellular biology and accelerate drug discovery, aiming to reduce the high failure rate of traditional methods.